Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review

References

• Bover J, Bailone L, López-Báez V, et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017;30(5):677–687. doi:10.1007/s40620-017-0404-z
   PubMed Web of Science ®Google Scholar
• Ginsberg C, Ix JH. Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J Kidney Dis. 2022;79(3):427–436. doi:10.1053/j.ajkd.2021.06.031
   PubMed Web of Science ®Google Scholar
• Lehmann G, Wolf G. Medikamentöse Therapie von Knochenstoffwechselstörungen bei CKD-MBD (“chronic kidney disease – mineral bone disorder“) unter besonderer Berücksichtigung antiresorptiver Wirkstoffe [Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances]. Z Rheumatol. 2014;73(4):329–334. German. doi:10.1007/s00393-013-1287-6
   PubMedGoogle Scholar
• Liu WC, Yen J-F, Lang C-L, et al. Bisphosphonates in CKD patients with low bone mineral density. Sci World J. 2013;2013:837573. doi:10.1155/2013/837573
   Google Scholar
• Moe SM. Renal Osteodystrophy or Kidney-Induced Osteoporosis? Curr Osteoporos Rep. 2017;15(3):194–197. doi:10.1007/s11914-017-0364-1
   PubMed Web of Science ®Google Scholar
• Khairallah P, Nickolas TL. Management of Osteoporosis in CKD. Clin J Am Soc Nephrol. 2018;13(6):962–969. doi:10.2215/CJN.11031017
   PubMed Web of Science ®Google Scholar
• Nitta K, Yajima A, Tsuchiya K. Management of osteoporosis in chronic kidney disease. Intern Med. 2017;56(24):3271–3276. doi:10.2169/internalmedicine.8618-16
   PubMed Web of Science ®Google Scholar
• Gonera-Furman A, Bolanowski M, Jedrzejuk D. Osteosarcopenia-the role of dual-energy X-ray Absorptiometry (DXA) in Diagnostics. J Clin Med. 2022;11(9):2522. doi:10.3390/jcm11092522
   PubMed Web of Science ®Google Scholar
• Broadwell A, Chines A, Ebeling PR, et al. Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab. 2021;106(2):397–409. doi:10.1210/clinem/dgaa851
   PubMed Web of Science ®Google Scholar
• Giusti A, Fusaro M. Il trattamento del paziente fratturato con insufficienza renale cronica (CKD) [The treatment of the patient presenting with chronic kidney disease (CKD) and fragility fractures]. G Ital Nefrol. 2017;34:1. Spanish.
   Google Scholar
• Gopaul A, Kanagalingam T, Thain J, et al. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. Arch Osteoporos. 2021;16(1):116. doi:10.1007/s11657-021-00971-0
   PubMed Web of Science ®Google Scholar
• Sessa C, Galeano D, Alessandrello I, et al. Osteoporosi e malattia renale cronica: vecchie e nuove strategie terapeutiche allo stato dell’arte [Osteoporosis and chronic kidney disease: review and new therapeutic strategies]. G Ital Nefrol. 2019;36:4. Italian.
   Google Scholar
• Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004;34(5):881–889. doi:10.1016/j.bone.2004.01.007
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. the alendronate Phase III osteoporosis treatment study group. N Engl J Med. 1995;333(22):1437–1443. doi:10.1056/NEJM199511303332201
   PubMed Web of Science ®Google Scholar
• Reid DM, Hosking D, Kendler D, et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS -international. Clin Drug Investig. 2006;26(2):63–74. doi:10.2165/00044011-200626020-00002
   PubMed Web of Science ®Google Scholar
• Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653–661. doi:10.1056/NEJMoa011807
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi:10.1056/NEJM200105103441904
   PubMed Web of Science ®Google Scholar
• Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765. doi:10.1056/NEJMoa0809493
   PubMed Web of Science ®Google Scholar
• Moe SM, Drüeke TB, Block GA, et al. Kidney disease: improving global outcomes, CKDMBDUWG, KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59. doi:10.1016/j.kisu.2017.04.001
   Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–342. doi:10.1038/nature01658
   PubMed Web of Science ®Google Scholar
• Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom. 2008;11(2):325–338. doi:10.1016/j.jocd.2008.02.002
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773–2783. doi:10.1007/s00198-015-3234-7
   PubMed Web of Science ®Google Scholar
• Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50–56. doi:10.1016/S0140-6736(13)60856-9
   PubMed Web of Science ®Google Scholar
• Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471–1479. doi:10.1002/jbmr.1613
   PubMed Web of Science ®Google Scholar
• Jamal SA, Ljunggren Ö, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829–1835. doi:10.1002/jbmr.403
   PubMed Web of Science ®Google Scholar
• Thongprayoon C, Acharya P, Acharya C, et al. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int. 2018;29(8):1737–1745. doi:10.1007/s00198-018-4533-6
   PubMed Web of Science ®Google Scholar
• Bonani M, Frey D, Brockmann J, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016;16(6):1882–1891. doi:10.1111/ajt.13692
   PubMed Web of Science ®Google Scholar
• Chen CH, Lo W-C, Hu P-J, et al. Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis. Front Pharmacol. 2022;13:822178. doi:10.3389/fphar.2022.822178
   PubMedGoogle Scholar
• Iseri K, Watanabe M, Yoshikawa H, et al. Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial. J Bone Miner Res. 2019;34(6):1014–1024. doi:10.1002/jbmr.3676
   PubMed Web of Science ®Google Scholar
• Takami H, Washio K, Gotoh H. Denosumab for male hemodialysis patients with low bone mineral density: a case-control study. Int J Nephrol. 2017;2017:6218129. doi:10.1155/2017/6218129
   PubMedGoogle Scholar
• Festuccia F, Jafari MT, Moioli A, et al. Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol. 2017;30(2):271–279. doi:10.1007/s40620-016-0334-1
   PubMed Web of Science ®Google Scholar
• Huynh AL, Baker ST, Stewardson AJ, et al. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016;25(11):1274–1278. doi:10.1002/pds.4045
   PubMed Web of Science ®Google Scholar
• Kunizawa K, Hiramatsu R, Hoshino J, et al. Denosumab for dialysis patients with osteoporosis: a cohort study. Sci Rep. 2020;10(1):2496. doi:10.1038/s41598-020-59143-8
   PubMed Web of Science ®Google Scholar
• Nanmoku K, Shinzato T, Kubo T, et al. Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients. Clin Nephrol. 2019;92(1):1–8. doi:10.5414/CN109723
   PubMed Web of Science ®Google Scholar
• Smyth B, Ong S. Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction. Intern Med J. 2016;46(3):360–363. doi:10.1111/imj.13001
   PubMed Web of Science ®Google Scholar
• Cohen A, Chacko B. Severe hypocalcaemia following denosumab and iron infusion. Nephrology. 2022;27(9):781–782. doi:10.1111/nep.14078
   PubMed Web of Science ®Google Scholar
• Hiramatsu R, Ubara Y, Sawa N, et al. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial. Am J Kidney Dis. 2015;66(1):175–177. doi:10.1053/j.ajkd.2015.03.012
   PubMed Web of Science ®Google Scholar
• Makras P, Polyzos SA, Papatheodorou A, et al. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol. 2013;79(4):499–503. doi:10.1111/cen.12188
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Kamimura M, Ikegami S, et al. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study. BMC Endocr Disord. 2015;15(1):81. doi:10.1186/s12902-015-0077-3
   PubMedGoogle Scholar
• Chen CL, Chen N-C, Liang H-L, et al. Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass. J Clin Endocrinol Metab. 2015;100(7):2784–2792. doi:10.1210/jc.2015-1259
   PubMed Web of Science ®Google Scholar
• Cianciolo G, Tondolo F, Barbuto S, et al. Denosumab-induced hypocalcemia and hyperparathyroidism in de novo kidney transplant recipients. Am J Nephrol. 2021;52(8):611–619. doi:10.1159/000518363
   PubMed Web of Science ®Google Scholar